68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks
Status:
Completed
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
Patients with primary prostate cancer (low, intermediate or high metastatic risk) for whom
radical prostatectomy is indicated, will be invited to participate to the present study.
Positron Emission Tomography coupled with scanner (PET-CT) using a radiotracer : 68Ga-RM2 and
Positron Emission Tomography coupled with scanner (PET-CT) using another radiotracer :
68Ga-PSMA-617, will be scheduled.